Detection and modulation of IAPs and NAIP for the diagnosis and treatment of proliferative disease
AssigneeAegera Therapeutics, Inc.
InventorsRobert G. Korneluk, Alexander E. Mackenzie, Peter Liston, Stephen Baird, Benjamin K. Tsang, Christine Pratt
Life of this patent
Estimating the term…
Abstract
Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.
Claims8
A method of enhancing apoptosis in a mammal, said mammal diagnosed as having a proliferative disease, said method comprising:
- providing a transgene encoding an antisense RNA, said antisense nucleic acid is complementary to a portion of a mammalian IAP nucleic acid sequence selected from the group consisting of:
- human X-linked IAP (XIAP) (SEQ ID NO:3), human IAP-1 (HIAP-1) (SEQ ID NO:5), human IAP-2 (HIAP-2) (SEQ ID NO:7);
- murine XIAP (SEQ ID NO:9), murine HIAP-1 (SEQ ID NO:11), and murine HIAP-2 (SEQ ID NO:13).
A method of inducing apoptosis in a cell, said cell in a mammal diagnosed with a proliferative disease, said method comprising administering to said cell An antisense nucleic acid of length sufficient to inhibit an inhibitor of apoptosis (IAP) biological activity in vitro, wherein said antisense nucleic acid is complementary to a portion of a mammalian IAP nucleic acid sequence selected from the group consisting of:
- human X-linked IAP (XIAP) (SEQ ID NO:3), human IAP-1 (HIAP-1) (SEQ ID NO:5), human IAP-2 (HIAP-2) (SEQ ID NO:7);
- murine XIAP (SEQ ID NO:9), murine HIAP-1 (SEQ ID NO:11), and murine HIAP-2 (SEQ ID NO:13).
Dependencies are inferred from the claim text.